Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: A retrospective, exploratory analysis in EMILIA

Annals of Oncology

Volumn 26, Issue 1, 2015, Pages 113-119

  Krop, Ian E ^a   Lin, N U ^a   Blackwell, K ^b   Guardino, E ^c   Huober, J ^d   Lu, M ^c   Miles, D ^e   Samant, M ^c   Welslau, M ^f   Dieras V ^g  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c GENENTECH INC   (United States)

^d CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^e MOUNT VERNON CANCER CENTRE   (United Kingdom)

^f Medical Office   (Germany)

^g INSTITUT CURIE   (France)

Author keywords

Ado trastuzumab emtansine; Central nervous system metastasis; Metastatic breast cancer; T DM1

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE PLUS LAPATINIB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; CAPECITABINE; DEOXYCYTIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; FLUOROURACIL; LAPATINIB; MAYTANSINE; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BREAST METASTASIS; CANCER PROGNOSIS; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EXPLORATORY RESEARCH; HAND FOOT SYNDROME; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SUBDURAL HEMATOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; SECONDARY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CAPECITABINE; CENTRAL NERVOUS SYSTEM NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MAYTANSINE; MIDDLE AGED; QUINAZOLINES; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84922507404     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu486     Document Type: Article

References (31)

1. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004; 22: 3608-3617.
2. Kennecke H, Yerushalmi R, Woods R et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010; 28: 3271-3277.
3. Weil RJ, Palmieri DC, Bronder JL et al. Breast cancer metastasis to the central nervous system. Am J Pathol 2005; 167: 913-920.
4. Eichler AF, Kuter I, Ryan P et al. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 2008; 112: 2359-2367.
5. Brufsky AM, Mayer M, Rugo HS et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 2011; 17: 4834-4843.
6. Olson EM, Najita JS, Sohl J et al. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the posttrastuzumab era. Breast 2013; 22: 525-531.
7. Pestalozzi BC, Holmes E, de Azambuja E et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol 2013; 14: 244-248.
8. Barnholtz-Sloan JS, Sloan AE, Davis FG et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004; 22: 2865-2872.
9. Miller KD, Weathers T, Haney LG et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 2003; 14: 1072-1077.
10. Aoyama H, Shirato H, Tago M et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006; 295: 2483-2491.
11. Dyer MA, Kelly PJ, Chen YH et al. Importance of extracranial disease status and tumor subtype for patients undergoing radiosurgery for breast cancer brain metastases. Int J Radiat Oncol Biol Phys 2012; 83: e479-e486.
12. Tsao MN, Lloyd N, Wong RK et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev 2012; 4: CD003869.
13. Polli JW, Humphreys JE, Harmon KA et al. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino} methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 2008; 36: 695-701.
14. Steeg PS, Camphausen KA, Smith QR. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer 2011; 11: 352-363.
15. Lin NU, Diéras V, Paul D et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009; 15: 1452-1459.
16. Bachelot T, Romieu G, Campone M et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 2013; 14: 64-71.
17. Lin NU, Freedman RA, Ramakrishna N et al. A phase I study of lapatinib with whole brain radiotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases. Breast Cancer Res Treat 2013; 142: 405-414.
18. Metro G, Foglietta J, Russillo M et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 2011; 22: 625-630.
19. Kirsch DG, Ledezma CJ, Mathews CS et al. Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol 2005; 23: 2114-2116.
20. Dawood S, Broglio K, Esteva FJ et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 2008; 19: 1242-1248.
21. Karam I, Nichol A, Woods R, Tyldesley S. Population-based outcomes after whole brain radiotherapy and re-irradiation in patients with metastatic breast cancer in the trastuzumab era. Radiat Oncol 2011; 6: 181.
22. 89Zrtrastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010; 87: 586-592.
23. Lewis Phillips GD, Li G, Dugger DL et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68: 9280-9290.
24. Junttila TT, Li G, Parsons K et al. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011; 128: 347-356.
25. Verma S, Miles D, Gianni L et al.; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-1791. Erratum in: N Engl J Med 2013; 368: 2442.
26. Pivot X, Semiglazov V, Zurawski B et al. CEREBEL (EGF111438): an open label randomized phase III study comparing the incidence of CNS metastases in patients (pts) with HER2+ metastatic breast cancer (MBC), treated with lapatinib plus capecitabine (LC) versus trastuzumab plus capecitabine (TC). In: Presented at the European Society of Medical Oncology 2012 Meeting; Vienna, Austria; 28 September-2 October, 2012. Abstract 3778.
27. Cameron D, Casey M, Press M et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112: 533-543.
28. Park YH, Park MJ, Ji SH et al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer 2009; 100: 894-900.
29. Musolino A, Ciccolallo L, Panebianco M et al. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer 2011; 117: 1837-1846.
30. Lockman PR, Mittapalli RK, Taskar KS et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 2010; 16: 5664-5678.
31. Bartsch R, Berghoff AS, Preusser M. Breast cancer brain metastases responding to primary systemic therapy with T-DM1. J Neurooncol 2014; 116: 205-206.